Literature DB >> 24576541

Comparison of outcomes in patients with ST-segment elevation myocardial infarction discharged on versus not on statin therapy (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial).

Alf I Larsen1, Matthew I Tomey2, Roxana Mehran3, Dennis W T Nilsen1, Ajay J Kirtane4, Bernhard Witzenbichler5, Giulio Guagliumi6, Sorin J Brener7, Philippe Généreux8, Ran Kornowski9, Dariusz Dudek10, Bernard J Gersh11, Gregg W Stone4.   

Abstract

Statin therapy is indicated after ST-segment elevation myocardial infarction (STEMI) to reduce recurrent ischemic events, but approximately 6% of patients with STEMI do not receive a statin prescription at discharge. This substudy aimed to define the clinical outcomes and patient characteristics associated with statin nonprescription after STEMI. We compared clinical, angiographic, and procedural characteristics and in-hospital, 30-day, 1-year, 2-year, and 3-year outcomes in 3,512 patients discharged after STEMI with and without (6%) statin prescriptions in the harmonizing outcomes with revascularization and stents in acute myocardial infarction trial (www.clinicaltrials.gov, NCT00433966). Statin nonprescription was associated with female sex, nonwhite race, previous bypass surgery, heart failure, renal impairment, anemia, thrombocytopenia, care in the United States, lower prescription rates of antiplatelets and neurohormonal antagonists, less percutaneous coronary intervention and stents, and, in 26% of cases, angiographically normal or nonobstructed coronary arteries. At every time point of follow-up after discharge, patients with no discharge statin prescription had significantly higher rates of net adverse clinical events, major adverse cardiac events, major bleeding unrelated to bypass surgery, and death. After multivariable adjustment, absence of a discharge statin prescription independently predicted 3-year major adverse cardiac event (hazard ratio 1.54, 95% confidence interval 1.15 to 2.07, p=0.0037) and death (hazard ratio 2.30, 95% confidence interval 1.41 to 3.77, p=0.0009). In conclusion, within the framework of this randomized trial of patients presenting with STEMI, approximately 6% of patients were discharged without statin therapy. Absence of a discharge statin prescription after STEMI was an independent predictor of ischemic events including death.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24576541     DOI: 10.1016/j.amjcard.2014.01.401

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Differential Outcomes by Race and Ethnicity in Patients with Coronary Heart Disease: A Contemporary Review.

Authors:  Heidi Mochari-Greenberger; Lori Mosca
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-05

2.  Prescription of statins at discharge and 1-year risk of major clinical outcomes among acute coronary syndromes patients with extremely low LDL-cholesterol in clinical pathways for acute coronary syndromes studies.

Authors:  Yihong Sun; Gaoqiang Xie; Anushka Patel; Shenshen Li; Wei Zhao; Xingzi Yang; Tao Wu; Min Li; Xian Li; Xin Du; Rong Hu; Yong Huo; Dayi Hu; Run Ling Gao; Yangfeng Wu
Journal:  Clin Cardiol       Date:  2018-09-22       Impact factor: 2.882

3.  ST-elevation versus non-ST-elevation myocardial infarction after combined use of statin with renin-angiotensin system inhibitor: Data from the Korea Acute Myocardial Infarction Registry.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  Cardiol J       Date:  2021-02-26       Impact factor: 3.487

4.  National Assessment of Statin Therapy in Patients Hospitalized with Acute Myocardial Infarction: Insight from China PEACE-Retrospective AMI Study, 2001, 2006, 2011.

Authors:  Lihua Zhang; Jing Li; Xi Li; Khurram Nasir; Haibo Zhang; Yongjian Wu; Shuang Hu; Qing Wang; Nicholas S Downing; Nihar R Desai; Frederick A Masoudi; John A Spertus; Harlan M Krumholz; Lixin Jiang
Journal:  PLoS One       Date:  2016-04-08       Impact factor: 3.240

5.  Statin therapy/lipid lowering therapy among Indian adults with first acute coronary event: The dyslipidemia Residual and Mixed Abnormalities IN spite of Statin therapy (REMAINS) study.

Authors:  Salgaonkar V Jaywant; A K Singh; Mundkur S Prabhu; R Ranjan
Journal:  Indian Heart J       Date:  2016-02-28

6.  Six-month adherence to Statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes.

Authors:  Gaoqiang Xie; Yihong Sun; Phyo Kyaw Myint; Anushka Patel; Xingzi Yang; Min Li; Xian Li; Tao Wu; Shenshen Li; Runlin Gao; Yangfeng Wu
Journal:  Lipids Health Dis       Date:  2017-08-15       Impact factor: 3.876

7.  Racial Difference in Symptom Onset to Door Time in ST Elevation Myocardial Infarction.

Authors:  Oluwaseyi Bolorunduro; Blake Smith; Mason Chumpia; Poojitha Valasareddy; Mark R Heckle; Rami N Khouzam; Guy L Reed; Uzoma N Ibebuogu
Journal:  J Am Heart Assoc       Date:  2016-09-30       Impact factor: 5.501

8.  Small Dense Low-Density Lipoprotein Cholesterol: A Residual Risk for Rapid Progression of Non-Culprit Coronary Lesion in Patients with Acute Coronary Syndrome.

Authors:  Teruo Sekimoto; Shinji Koba; Hiroyoshi Mori; Rikuo Sakai; Taito Arai; Yuya Yokota; Shunya Sato; Hideaki Tanaka; Ryota Masaki; Yosuke Oishi; Kunihiro Ogura; Ken Arai; Kosuke Nomura; Ryota Kosaki; Koshiro Sakai; Hiroaki Tsujita; Seita Kondo; Shigeto Tsukamoto; Fumiyoshi Tsunoda; Makoto Shoji; Hidenari Matsumoto; Yuji Hamazaki; Toshiro Shinke
Journal:  J Atheroscler Thromb       Date:  2021-02-05       Impact factor: 4.928

9.  Monotherapy versus combination therapy of statin and renin-angiotensin system inhibitor in ST-segment elevation myocardial infarction.

Authors:  Yong Hoon Kim; Ae-Young Her; Myung-Ho Jeong; Byeong-Keuk Kim; Sung-Jin Hong; Seunghwan Kim; Chul-Min Ahn; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Myeong-Ki Hong; Yangsoo Jang
Journal:  Cardiol J       Date:  2020-03-24       Impact factor: 2.737

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.